Key result
A systematic review of 167 articles evaluated the influence of coagulatory alterations, lipid metabolism, and therapies like SGLT2 and PCSK9 inhibitors on cardiovascular risk in diabetes mellitus.
Why the study?
The authors sought to understand how diabetes influences cardiovascular alterations, coagulatory parameters, and related pathways to determine prophylaxis needed to avoid cardiovascular complications.
Does targeting coagulatory alterations and using specific therapies (SGLT2i, PCSK9i) prevent cardiovascular disease in patients with Type 1 and Type 2 Diabetes Mellitus?
Systematic Review (n=167)
Does targeting coagulatory alterations and using specific therapies (SGLT2i, PCSK9i) prevent cardiovascular disease in patients with Type 1 and Type 2 Diabetes Mellitus?
This systematic review highlights the importance of targeting coagulatory alterations, lipid metabolism, and utilizing therapies like SGLT2 and PCSK9 inhibitors to prevent cardiovascular disease in patients with diabetes.
Answers are grounded in this paper and cite their sources.
Supports coagulation/lipid targeting plus SGLT2i/PCSK9i for CV risk reduction in diabetes; reinforces comprehensive prevention strategies.
.Further we reviewed how CVD is avoided with better Sodium Glucose Transporter 2( SGLT2) inhibitors in both T1DM as well as T2DM. Further we have emphasized on use of weight neutral hypoglycaemics to reduce the morbidity with escalation of diabesity. Also we reviewed importance of microRNA'S, inHDL transport, significance of use of proprotein convertase subtilisin /kexin type9(PCSK9) inhibitors Here we tried to concentrate on reducing same by understanding how this DM might influence the cardiovascular System( CVS) alterations as well as changes caused by them in the amounts of plasma proteins as well as metal ions, changed lipid metabolism(causing changed metabolic control), cardiac lipotoxicity as well as atherosclerosis, endothelial impairment, platelets hyperreactivation along with the existence of procoagulant particles in the blood in aetiopathogenesis of CVD with lipid metabolism, sphingosine-1 phosphate ;alteration in coagulation parameters in both T1DM as well as T2DM. Thus we conducted a systematic review regarding same with utilization of search engines like pubmed, MEDLINE, Google scholar, Web of Science, scopus, Embase, using MeSH terms like fibrinogen; thrombin; antithrombin; antiplasmin; plasminogen activator inhibitor -1 (PAI-1), von Willebrand factor ; factor V, factor VII, factor IX, factor X factor, factor XII,tissue factor, metal ions like Ca2+ATPase, Zn2+, Cu2+, Mg2+, Fe3+ iron, platelet hyperactivation; platelet microparticles; complement alteration; endothelial impairment role of lipid metabolism LDL levels, High density lipoproteins High density lipoproteins (HDL) levels in type1 diabetes mellitus as well as type2 diabetes mellitus as well as from 1980's till 2029 till date. We found a total of 650 articles out of which we selected 167 articles for this review. No metaanalysis was done. Thus we consider each step by step in influencing CVS risk and what prophylaxis is needed to avoid the CVD complications in each of DM along with influence in COVID mortality.
No takes yet. Share an insight, caveat, or question.
Kaur et al. (2020) conducted a systematic review in Type 1 and Type 2 Diabetes Mellitus (n=167). Cardiovascular disease prophylaxis (SGLT2 inhibitors, PCSK9 inhibitors, targeting coagulatory alterations) was evaluated. A systematic review of 167 articles evaluated the influence of coagulatory alterations, lipid metabolism, and therapies like SGLT2 and PCSK9 inhibitors on cardiovascular risk in diabetes mellitus.
Synapse has enriched 10 related papers. Consider them for comparative context: